Eva Pharma
- Company typePrivate
- Founded1997
- HeadquartersGîza, Egypt
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Eva Pharma firmographics
Firmographics- Name
- Eva Pharma
- Legal name
- Eva Pharma
- Website
- https://evapharma.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Eva Pharma industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where Eva Pharma is headquartered
LocationHeadquarters
- HQ city
- Gîza
- HQ country
- Egypt
- HQ region
- Africa
Offices8 records
Markets served
Eva Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Manufacturing and sale of pharmaceutical products including generics, biologics, and specialty medicines across therapeutic areas
- Generic Drug Manufacturing: Production of generic versions of patented drugs under voluntary licensing agreements for HIV, diabetes, and other diseases in low-to-middle-income countries
- CDMO/Contract Manufacturing: Contract development and manufacturing organization services for pharmaceutical development and commercialization in MENA region
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Eva Pharma product offering
Product offeringCore offering
Eva Pharma manufactures and distributes a portfolio of 300+ pharmaceutical products across 12 therapeutic areas including oncology, anti-infectives, cardiometabolic medicine, neuroscience, respiratory, ophthalmology, bone health, hepatology, and reproductive health. The company operates vertically integrated manufacturing from API to finished products across EU-GMP certified facilities in Egypt and Saudi Arabia, producing over 1 million packs daily for distribution to 40+ countries with focus on low-to-middle-income markets.
Product overview
EVA Pharma is a global pharmaceutical company operating as a single unified product portfolio across multiple therapeutic areas. The company manufactures and distributes pharmaceutical products through its vertically integrated operations including EU-GMP certified manufacturing facilities, research centers, and distribution networks. Key product lines include EVA Pharma Oncology (immunotherapy and oncology treatments), insulin products (glargine and human insulin), and lenacapavir (HIV treatment). The company offers CMO/CDMO contract manufacturing services and operates the mRNA Innovation Hub for vaccine development. With 300+ products in portfolio and 500+ in pipeline, the company serves 40+ countries with a focus on 12 therapeutic areas: anti-infectives, metabolic health, bone health, neuroscience, oncology, respiratory, gynecology, urology/andrology, pediatrics, ophthalmology, gastrointestinal tract, and family medicine.
Differentiator
Problem solved
Functional benefit
Brands
- EVA Pharma Oncology: Specialized oncology sector launched in November 2025, focusing on immunotherapy, hematology, and oncology treatments for critical medicines sustainable access.
- Limitless Naturals
- Horus Facility
Products and services
- EVA Pharma Oncology
- Insulin Glargine Injection (Glargivin)
- Lenacapavir
- mRNA Vaccines
- Anti-infectives Portfolio
- Cardiometabolic Medicines
- Oncology Products
- Neuroscience Products
- Respiratory Products
- Ophthalmology Products
- Bone Health and Pain Management Products
- Hepatology Products
- Reproductive Health Products
- CMO/CDMO Services
Quantifiable outcome
- Oncology production capacity of 22 million packs annually with 18 specialized cancer products developed
- +3 more outcomes
Companies that use Eva Pharma
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
Eva Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Eva Pharma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic and core.
- BMZ (German Federal Ministry for Economic Cooperation and Development)strategicHigh-level delegation visit to EVA Pharma manufacturing facilities. Visit on sidelines of WHO Global Private Sector Engagement Forum under Global Gateway framework. Focus on EVA Pharma's role as strategic African hub for pharmaceutical manufacturing and technology transfer.
- GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)strategicGerman development organization visited EVA Pharma facilities to explore localized manufacturing role in building resilient health systems. Delegation included Director General for Sustainable Development and Climate at BMZ.
- World Health Organization (WHO)coreCollaboration on WHO pre-qualification for locally manufactured human insulin injection. Pre-qualification ensures medicines meet WHO quality standards for international procurement.
- Gilead SciencescoreRoyalty-free voluntary licensing agreement for lenacapavir manufacturing and supply. EVA Pharma is the sole African licensee, authorized to manufacture API and finished products for 120 high-incidence, resource-limited countries. Includes technology transfer for sustainable accessibility to HIV treatment and prevention.
- Eli Lilly and CompanycoreCollaboration for local insulin manufacturing in Egypt. Lilly supplies API at reduced prices and provides pro-bono technology transfer for formulation, fill and finish of insulin vials and cartridges. First regulatory approval obtained December 2024 for insulin glargine injection. Target of 1 million people annually across 56 countries by 2030.
Scale indicators11 records
Recent moves9 records
Eva Pharma competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Eva Pharma social profiles
Digital presenceEva Pharma compliance and trust
Trust signalCompliance3 records
Eva Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eva Pharma leadership team
Management profileNumber of profiles
Profiles16 records
Eva Pharma subsidiaries and ownership
Company hierarchySubsidiaries11 records
Eva Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eva Pharma M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eva Pharma
What does Eva Pharma do?
Eva Pharma manufactures and distributes a portfolio of 300+ pharmaceutical products across 12 therapeutic areas including oncology, anti-infectives, cardiometabolic medicine, neuroscience, respiratory, ophthalmology, bone health, hepatology, and reproductive health. The company operates vertically integrated manufacturing from API to finished products across EU-GMP certified facilities in Egypt and Saudi Arabia, producing over 1 million packs daily for distribution to 40+ countries with focus on low-to-middle-income markets.
Is Eva Pharma a public or private company?
Eva Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Eva Pharma founded?
Eva Pharma was founded in 1997. It employs 1,001 to 5,000 people.
Where is Eva Pharma based?
Eva Pharma is headquartered in Gîza, Egypt, in the Africa region.
How does Eva Pharma make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are generic Drug Manufacturing and CDMO/Contract Manufacturing.
Does Eva Pharma have an API?
No public API is recorded for Eva Pharma.
What industry is Eva Pharma in?
Eva Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 325412 and its SIC code is 2834.